Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: FTSE 100 nears one-month high

Tue, 10th Sep 2013 11:39

Receding fears about a potential US military strike on Syria and decent data from China lifted UK stocks on Thursday morning, with the FTSE 100 rising to levels not seen in nearly a month.London's benchmark index was up 0.8% at 6,581.91 by midday; the last time it closed higher was on August 14th when it ended the day at 6,587.43.Russian Foreign Minister Sergei Lavrov yesterday urged Syria to place any chemical weapons they may have under international control in an attempt to avoid action from the States. The news that Syrian counterpart Walid Muallem apparently welcomed the proposal eased concerns over a possible Western intervention this morning, especially given that President Barack Obama said that he would put air strikes on hold if Bashar al-Assad's government follows the initiative."Stocks rallied on the back of this, as investors don't want another war on their hands, and this recommendation from the Russians could sidestep military intervention while saving face," said Market Analyst David Madden from IG.Supporting stocks further was a continuing improvement in economic data from China with the third-quarter outlook for the Asian powerhouse continuing to brighten. Industrial output, fixed-asset investment and retail sales strengthened during the month of August, with all three economic indicators rising by more than expected.Market Strategist Ishaq Siddiqi from ETX Capital said that this morning's data "indicat[es] the world's second-largest economy is finally back above its knees after a turbulent first half of 2013.""China's policymakers are attempting to transform the country's economy into one based on consumption over the current model based on spending and the macro indicators are suggesting that these measures are starting to bear fruit," he said.FTSE 100: Airlines IAG and easyJet flying highAirline groups IAG and easyJet were flying higher this morning as crude continued to pull back from its recent highs as fears over turmoil in the Middle East ease. Elevated oil prices have pressured both stocks over the last few weeks on concerns over the knock-on effects to jet fuel costs. Shares in easyJet were also helped by comments from Chief Executive Carolyn McCall who said in an interview that the company will be "Europe's preferred airline in five years' time" due to its low-cost operating model.Financials were also performing well today with RBS, Standard Chartered, Aviva, Aberdeen Asset Management and Schroders among the highest risers.Leading the downside was pharma giant GlaxoSmithKline which fell sharply after US regulators set out requirements for generic versions of its lung drug Advair, sparking competition concerns over when patents run out in a few years' time.Costa and Premier Inn owner Whitbread was also down after seeing sales growth slow from 13.8% in the first quarter to just 10.8% in the second as the hot summer weather hit demand at its coffee shops.Miners were putting in a mixed performance as increased risk appetite was offset by falling metals prices across the board. Glencore Xstrata was in demand after lifting its synergy target - following its merger - to at least $2bn next year as the miner vowed to cut costs and improve operational efficiency. Precious metals groups Fresnillo and Randgold, however, were out of favour. Rolls-Royce gained after scoring a $175m contract with Asia Gas Pipeline (AGP) for services on a natural gas pipeline in Kazakhstan.Broker comments were also moving a number of blue-chip stocks this morning: Drinks giant SABMiller was on the climb this morning after HSBC upgraded the stock to 'overweight'; consumer products group Unilever was lifted by Deutsche Bank to 'buy'; and Babcock was higher after JPMorgan labelled the engineering support services company as its top pick in the sector.FTSE 250: Ashmore jumps, Oxford Instruments slumpsRecord subscriptions helped emerging markets asset manager Ashmore to drive strong net inflows into its funds in the year to June, giving the share price a boost this morning. Strong net inflows of $13.4bn led to a 22% increase in assets under management (AuM) to $77.4bn during the year, with average AuM rising 13%.Oxford Instruments was a heavy faller after saying that while growth in the order intake rate in Industrial Products and third party Service is encouraging, slowness in R&D markets in the Western economies means that the year is likely to be more second half-weighted.FTSE 100 - RiserseasyJet (EZJ) 1,335.00p +5.37%International Consolidated Airlines Group SA (CDI) (IAG) 319.50p +4.58%Standard Chartered (STAN) 1,502.00p +3.19%Royal Bank of Scotland Group (RBS) 350.80p +3.18%Aviva (AV.) 412.10p +3.08%Aberdeen Asset Management (ADN) 380.40p +3.03%British Land Co (BLND) 574.00p +2.96%Glencore Xstrata (GLEN) 330.10p +2.74%Schroders (SDR) 2,486.00p +2.64%Marks & Spencer Group (MKS) 513.00p +2.50%FTSE 100 - FallersGlaxoSmithKline (GSK) 1,590.00p -3.05%Whitbread (WTB) 3,129.00p -2.71%Fresnillo (FRES) 1,249.00p -1.58%Eurasian Natural Resources Corp. (ENRC) 222.60p -0.98%Randgold Resources Ltd. (RRS) 4,869.00p -0.92%Vodafone Group (VOD) 209.00p -0.67%BG Group (BG.) 1,213.00p -0.33%Bunzl (BNZL) 1,353.00p -0.29%BP (BP.) 443.00p -0.25%Vedanta Resources (VED) 1,189.00p -0.08%FTSE 250 - RisersOcado Group (OCDO) 374.20p +6.91%Ashmore Group (ASHM) 387.60p +6.81%Fenner (FENR) 390.40p +5.26%Thomas Cook Group (TCG) 157.50p +5.07%Inchcape (INCH) 641.00p +4.74%Ferrexpo (FXPO) 186.60p +4.42%Laird (LRD) 233.30p +4.34%Galliford Try (GFRD) 1,066.00p +4.20%Berendsen (BRSN) 940.50p +3.75%Betfair Group (BET) 1,050.00p +3.55%FTSE 250 - FallersOxford Instruments (OXIG) 1,423.00p -5.76%African Barrick Gold (ABG) 175.00p -4.68%Rank Group (RNK) 155.00p -2.58%PayPoint (PAY) 1,086.00p -1.63%Moneysupermarket.com Group (MONY) 170.00p -1.33%BH Macro Ltd. EUR Shares (BHME) € 20.78 -1.28%Telecom Plus (TEP) 1,337.00p -1.26%Telecity Group (TCY) 836.50p -1.18%BH Macro Ltd. GBP Shares (BHMG) 2,140.00p -1.02%BH Global Ltd. GBP Shares (BHGG) 1,181.00p -1.01%BC
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.